08 December 2023
The BSR Biologics and Biosimilars Registers are currently active in collaborating with other researchers around the world to help add to the wealth of knowledge about the effectiveness and safety of treatments for Rheumatoid Arthritis (RA), ankylosing spondylitis (AS) and Juvenile Idiopathic Arthritis (JIA).
An important aim of the registers and our university partner organisations, Manchester and Aberdeen, is to add as much evidence as possible to the understanding of the best way to treat such conditions safely.
Currently, there are three large-scale collaborations to which these registers are active contributors:
The JAK-pot collaboration, a 19-country partnership of international research institutions is examining the real-world effectiveness and safety of JAK inhibitors versus TNF inhibitors and other biologic DMARDs in RA.
The BSRBR-AS continues to contribute to EuroSpA, a 16-country collaboration that has a significant pipeline of planned publications; the collaboration brings together data from international registers to explore important research questions that would remain unanswered without this cooperation.
Meanwhile, the Cluster Consortium, funded by the UK Research and Innovation body and Versus Arthritis, is investigating precision medicine in children. Six UK universities and five pharmaceutical companies are actively taking part. This work will help improve our understanding of how best to treat JIA-Uveitis and JIA.
Our registers will continue to collaborate and contribute data to both national and international projects such as these to advance our understanding of rheumatology research.